# Victoria P. Werth

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/victoria-p-werth/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,815 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 83 |
| i10-index | 345 |
| Last Known Institution | Hospital of the University of Pennsylvania |
| OpenAlex ID | https://openalex.org/A5029793095 |
| ORCID iD | 0000-0003-3030-5369 |
| Works | 791 |

## Researcher papers

Showing 12 of 17.

- [Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/derivation-and-validation-of-the-systemic-lupus-international-collaborating/)
- [2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups](https://scholariq.org/papers/2017-european-league-against-rheumatism-american-college-of-rheumatology/)
- [Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus](https://scholariq.org/papers/anifrolumab-an-anti-interferon-receptor-monoclonal-antibody-in-moderate-to/)
- [2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups](https://scholariq.org/papers/2017-european-league-against-rheumatism-american-college-of-rheumatology-2/)
- [Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus](https://scholariq.org/papers/consensus-statement-on-definitions-of-disease-end-points-and-therapeutic/)
- [The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus](https://scholariq.org/papers/the-clasi-cutaneous-lupus-erythematosus-disease-area-and-severity-index-an/)
- [Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study](https://scholariq.org/papers/sifalimumab-an-anti-interferon-monoclonal-antibody-in-moderate-to-severe/)
- [Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C‐HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF‐36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index‐2 (FI‐2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)](https://scholariq.org/papers/measures-of-adult-and-juvenile-dermatomyositis-polymyositis-and-inclusion-body/)
- [Update on morphea](https://scholariq.org/papers/update-on-morphea/)
- [Diagnosis and management of pemphigus: Recommendations of an international panel of experts](https://scholariq.org/papers/diagnosis-and-management-of-pemphigus-recommendations-of-an-international-panel/)
- [Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts](https://scholariq.org/papers/definitions-and-outcome-measures-for-bullous-pemphigoid-recommendations-by-an/)
- [2021 DORIS definition of remission in SLE: final recommendations from an international task force](https://scholariq.org/papers/2021-doris-definition-of-remission-in-sle-final-recommendations-from-an/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Inflammatory Myopathies and Dermatomyositis](https://scholariq.org/topics/inflammatory-myopathies-and-dermatomyositis/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

## Researcher university

- [Hospital of the University of Pennsylvania](https://scholariq.org/institutions/hospital-of-the-university-of-pennsylvania/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.